Preclinical studies corroborated that PI3K, MAPK, and NOTCH were significantly overexpressed in HR−/HER2 + breast cancer, which could be potentially correlated to therapeutic resistance and lead to the poor survival outcome [41]. The gene discussed is ERBB2; the disease is breast carcinoma.